Delivering the promise
Inception of Alkem Laboratories Limited
First manufacturing unit was established at Taloja near Mumbai
Second manufacturing facility established at Mandva, Gujarat which was converted into an API facility in 2005
First research and development facility established at Taloja
Taxim became India’s first anti-infective drug to surpass sales figure of ₹ 1,000 million in the domestic market
Filed the first ANDA in the United States for the drug Amlodipine
Received the first ANDA in the United States for the drug Amlodipine
Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia
Acquired Ascend Laboratories, pharmaceutical company in the United States
Acquired Enzene, a company engaged in the development of biosimilars in India
Acquired an API manufacturing facility in the United States
Acquired the ‘Clindac-A’ brand in India from Galderma S.A.
Clavam surpassed ₹ 2,000 million domestic sales figure
Acquired a formulation manufacturing facility in the United States
Successfully completed Initial Public Offering (IPO)
Marketing alliance with Haw Par to exclusively market, sell and distribute Tiger Balm range of products in India
Direct consumer marketing for Pregakem and Livoerb
Revenue from the US market crossed US$ 200 mn in annual sales
Crossed the revenue milestone of US$1 billion
Started new formulation manufacturing facility in Indore
Started a new biologic/biosimilar manufacturing facility in Pune
First product launched from Enzene Biosciences in India
Company forayed in the respiratory segment in India with the launch of Pulmocare division
Clavam crossed ₹6 billion sales milestone
Awarded as “Pharma Company of the Year” in ET India Pharma World Awards 2023
Company forayed in the Ophthalmology segment in India with the launch of Eyecare division